Clinical data | |
---|---|
Trade names | Habekacin |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intramuscular, intravenous |
Drug class | Aminoglycoside antibiotic |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Metabolism | minimal |
Excretion | Renal |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
PDB ligand | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C22H44N6O10 |
Molar mass | 552.626 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Arbekacin (INN) is a semisynthetic aminoglycoside antibiotic which was derived from kanamycin. It is primarily used for the treatment of infections caused by multi-resistant bacteria including methicillin-resistant Staphylococcus aureus (MRSA).[1][2] Arbekacin was originally synthesized from dibekacin in 1973 by Hamao Umezawa and collaborators.[3] It has been registered and marketed in Japan since 1990 under the trade name Habekacin.[4] Arbekacin is no longer covered by patent and generic versions of the drug are also available under such trade names as Decontasin and Blubatosine.